Journal of pharmacological and toxicological methods
January 1, 2019
Anna Šuláková, Lucie Fojtíková, Barbora Holubová et al.
11 citations
Two new immunoassays, a lateral flow immunoassay (LFIA) and an enzyme-linked immunosorbent assay (ELISA), were developed to detect the hallucinogenic phenethylamine 2C-B and related drugs in urine. The LFIA provides rapid on-site screening with a detection limit of 15 ± 7 ng mL⁻¹, suitable for identifying recent exposure. The ELISA offers much higher sensitivity, with a detection limit of 6 ± 3 pg mL⁻¹, and its results closely match those from established UHPLC-MS-MS analysis, making it reliable for quantitative confirmation in toxicology. Both methods address the need for simple, cost-effective tools to monitor these dangerous substances.
Journal of pharmacological and toxicological methods
January 1, 2016
Simon Authier, Michael V Accardi, Dominique Paquette et al.
10 citations
In cynomolgus monkeys, noribogaine—a drug being developed for opioid dependence—did not cause seizures or EEG signals that warn of increased seizure risk, even at the highest dose tested (320 mg/kg). Monkeys showed mild behavioral effects such as reduced activity, scratching, licking, chewing, and some poor coordination. One monkey had brief myoclonic movements at the high dose, but these did not spread or link to EEG abnormalities. In contrast, the positive control pentylenetetrazol consistently triggered seizure-related EEG patterns and generalized seizures. The study establishes 320 mg/kg as the EEG no observed adverse effect level for noribogaine in this model.
Journal of pharmacological and toxicological methods
January 1, 2020
S S Rowton, B A Rocha, I E Porter
Ten female rats were trained to distinguish the effects of Δ9-THC from no drug. Once trained, they received various doses of Δ9-THC, followed by amphetamine, morphine, midazolam, and three synthetic cannabinoids (WIN55,212-2, CP-47,497, and JWH-018). The non-cannabinoid drugs produced responses similar to the no-drug condition, confirming specificity. JWH-018 fully substituted for Δ9-THC, but WIN55,212-2 and CP-47,497 did not, contrary to some published findings. The authors question the reliability of drug discrimination and self-administration tests for assessing the abuse potential of novel cannabinoid-like drugs, given the unpredictable behavioral effects of cannabinoids in animals and humans.